In a report released on April 1, David Risinger from Leerink Partners maintained a Buy rating on AnaptysBio (ANAB – Research Report). The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback